Navigation Links
OncoGenex in Medical News

BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company

...in net proceeds from the sale of common stock to a subsidiary of Cadila Pharmaceuticals as part of a new strategic alliance. On July 20, 2009, oncogenex Pharmaceuticals, Inc. raised approximately $9 million in net proceeds from a direct common stock offering to certain institutional investors. O...

Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO

...-427 are antisense drugs co-discovered by Isis and oncogenex (Nasdaq: OGXI ) and Isis licensed its rights to OGX-011 to oncogenex Pharmaceuticals, Inc. In addition, new results f...s with cancer were also presented. Both Lilly and oncogenex are also developing additional anti-cancer drugs i...

Isis Reports Strong Financial Results and Highlights for First Quarter of 2009

...hat showed iCo-007 appears to be well tolerated and demonstrates promising signs of activity in patients with diffuse diabetic macular edema. oncogenex reached an agreement with the FDA on the design of a second Phase 3 registration trial of OGX-011 that features durable pain palliation as the primary...

Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology

...the annual ASCO meeting in Chicago. Both Lilly and oncogenex are developing additional anticancer drugs discove... antisense drugs being developed by Isis' partners oncogenex and Lilly continue to demonstrate the potential of antisense technology to treat multiple cancers. oncogenex presented Phase 2 data on OGX-011 demonstrating be...

Isis Reports Financial Results and Highlights for First Quarter of 2008

... -- Isis received a $2 million milestone payment with the selection of an antisense drug candidate to advance into development. o oncogenex reported encouraging Phase 2 data of OGX-011, an antisense drug in clinical studies in patients with advanced prostate or lung cancers. ...

Isis Reports Financial Results and Highlights for Fiscal year 2007

...rugs discovered by Isis to treat cancer. * oncogenex reported encouraging Phase 2 data for OGX-011, an ...y agents alone, based on historical controls. * oncogenex initiated Phase 1 clinical studies of OGX-427, an ...ntial of antisense drugs. Already this year, oncogenex reported Phase 2 results for OGX-011 in prostate ...
OncoGenex in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...ned $1.4 million of revenue when Isis sold drug to oncogenex Pharmaceuticals, Inc. Isis' re...cal Oncology (ASCO) annual meeting. oncogenex reported results of a randomized Phase 2 trial of ...for patients treated with docetaxel alone. oncogenex reported that OGX-427 was well tolerated as a mono...

Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

...icals, Inc. (Nasdaq: ISIS ) announced today that oncogenex Pharmaceuticals, Inc. provided positive survival r...he latest results from OGX-011 and look forward to oncogenex announcing the full results of the study next year...llow-up of approximately 30 months for both arms. oncogenex indicates that additional survival updates will be...

OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting

... VANCOUVER, April 17, 2007 /PRNewswire/ - oncogenex Technologies Inc. announced today data from a Phas...ing chemotherapy, and facilitate tumor cell death. oncogenex is developing OGX-011 in collaboration with Isis P...rt provided by OncoGenex Technologies Inc. About oncogenex ...

OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO

...ARLSBAD, CA, May 31, 2007 /PRNewswire-FirstCall/ - oncogenex Technologies Inc. and Isis Pharmaceuticals, Inc. t...ing chemotherapy, and facilitate tumor cell death. oncogenex and Isis are collaborating on development of OGX-011. About oncogenex ...
OncoGenex in Biological Technology

FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011

BOTHELL, WA and VANCOUVER, Aug. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI ) announced today that OGX-011, also known as custirsen sodium, received Fast Track designation from the U.S. Food & Drug Administration (FDA) in combination with docetaxel for progressive meta...

Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today

Satisfies initial listing requirements with NASDAQ; Stock Symbol 'OGXI' Implements immediate restructuring program, which extends cash runway while focusing on clinical pipeline programs BOTHELL, WA, Aug. 21 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceut...

Sonus Pharmaceuticals and OncoGenex Technologies to Merge

- Combined Company Will Have Three Oncology Products in Clinic - - Lead Candidate Targets Hormone Refractory Prostate and Non-Small Cell Lung Cancers - - Conference Call to be Held Wednesday, May 28th, at 11:00 a.m. Pacific Time...

OncoGenex Reports Second Quarter 2009 Financial Results

...WA, and VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company...ing consolidated results reflect the operations of oncogenex Technologies Inc. ("OncoGenex Technologies") prior...s, Inc. ("Sonus"), and the consolidated results of oncogenex thereafter. The loss attributable to common shar...

OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results

... WA and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals (NASDAQ: OGXI ) announced today ...ter financial results on Thursday, August 6, 2009. oncogenex will host a conference call and live webcast at 4:... be accessed on the Investor Relations page of the oncogenex Web site at www.oncogenex.com . Alternatively, yo...

OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering

...WA and VANCOUVER, July 24 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced ... purposes. The shares of common stock offered by oncogenex in this transaction were offered and sold pursuant...ission's web site at http://www.sec.gov , or from oncogenex Pharmaceuticals, Inc., 1522 217th Pl. SE, Suite 10...

OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock

...WA and VANCOUVER, July 20 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced ...ected to provide gross proceeds of $9.5 million to oncogenex before deducting costs associated with the offerin... 24, 2009. The shares of common stock offered by oncogenex in this transaction will be issued pursuant to the...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...g Receives FDA Approval for Degarelix in Prostate Cancer II-53 Isis and oncogenex Reveals Positive results of OGX-011 Molecule in HRPC II-53 Antisoma... BioWa Obtains License for Anti-FGF8 Antibody from Kyowa Hakko II-87 oncogenex and Isis Pharmaceuticals Expand Partnership II-87 Caprion and AstraZene...

OncoGenex Pharmaceuticals Added to Russell Indexes

...A, and VANCOUVER, June 30 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals, Inc. (NASDAQ: OGXI ), a biophar...l.com/Indexes/performance/default.asp . About oncogenex oncogenex is a biopharmaceutical company committed to the de...

OncoGenex Pharmaceuticals Files Shelf Registration Statement

...WA and VANCOUVER, June 26 /PRNewswire-FirstCall/ - oncogenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced ...o fund our Phase 3 clinical trials for OGX-011." oncogenex elected to terminate its previous shelf registrati...ent and MJDS prospectus, respectively, will permit oncogenex Pharmaceuticals to sell, from time to time over a ...
Other Tags
(Date:7/10/2014)... benefits of medical imaging far outweigh the risks when ... with The Right Radiation Dose. However, overuse and misuse ... is leading a collaborative effort to ensure a national ... in the Journal of Patient Safety , calls ... the Intersociety Accreditation Commission, and the Centers for Medicare ...
(Date:7/10/2014)... For decades, health-conscious people around the globe have taken ... this was one of the paths to good health ... trials of antioxidant supplements have repeatedly dashed the hopes ... cancer risk. Virtually all such trials have failed ... fact, in several trials antioxidant supplementation has been linked ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to talk ... their silent suffering if they are willing to ... Baylor University case study., After seven weeks of hypnotic ... flashes following prostate cancer surgery showed a drastic decrease ... improvement in sleep quality, according to the study., The ...
(Date:7/9/2014)... Vasectomy was associated with a small increased risk of ... lethal prostate cancer according to a new study from ... that the association remained even among men who received ... cancer cannot be explained by diagnostic bias. It is ... look at the link between vasectomy and prostate cancer. ...
(Date:7/9/2014)... of lung cancer, researchers have uncovered mutations in a ... The new knowledge may expand treatments for patients because ... available or are in clinical trials. , Reporting July ... Genome Atlas (TCGA), including researchers at Washington University School ... other institutions, studied tumors from 230 patients with lung ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Lung cancer study hints at new treatments 2
(Date:7/9/2014)... selection for traits that are attractive to the opposite ... to mate, the tail of male peacocks being an ... Riverside have now found that sexual selection and "placentation" ... Describing the life histories of more than 150 species ... that species with placentas tend to have males that ...
(Date:7/9/2014)... A crucial piece of the puzzle behind nature,s ... that could help advance the development of artificial ... been provided by an international collaboration of scientists ... Laboratory (Berkeley Lab) and the SLAC National Accelerator ... Light Source (LCLS), the world,s most powerful x-ray ...
(Date:7/9/2014)... Researchers studying critically ill children with traumatic injuries ... patients are likely to develop a hospital-acquired infection. ... Hospital and published online in June in the ... larger efforts that could lead to the clinical ... to prevent or reverse immune system damage following ...
Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
Other Contents